EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
Globe Newswire•30/07/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.